510. Deputy Ken O'Flynn asked the Minister for Health the incremental cost-effectiveness ratio, cost per QALY gained, time horizon applied, and discount rate used in the full health technology assessments conducted by the National Centre for Pharmacoeconomics in respect of tirzepatide for type 2 diabetes mellitus and weight management; and whether lifetime modelling assumptions were applied in either assessment. [15811/26]

Summary

510. Deputy Ken O'Flynn asked the Minister for Health the incremental cost-effectiveness ratio, cost per QALY gained, time horizon applied, and discount rate used in the full health technology assessments conducted by the National Centre for Pharmacoeconomics in respect of tirzepatide for type 2 diabetes mellitus and weight management; and whether lifetime modelling assumptions were applied in either assessment. [15811/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 26 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.